Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Breast Cancer is the most common cancer found in women, regardless
of race or ethnicity. According to the National Cancer Institute, an
estimated 281,550 new cases of invasive breast cancer are to be
diagnosed in women in the United States during 2021. The incidence
in women in the United States is 1 in 8 (about 13 percent). About
43,600 women are expected to die from breast cancer this year,
though death rates have been steadily decreasing over the past 20
years due to new and ever improving treatment options. However, in
the later stages of disease, when distant metastases are present,
cure becomes less likely, and few patients are rendered free of
disease. Fortunately for advanced breast cancer patients with
HR+/HER2- advanced breast cancer, several new agents, including CDK
4/6 inhibitors, have changed the paradigm in the last 10 years, and
recent real-world data has been released that shows the strong
efficacy and safety of these options. This webinar series will
provide managed care professionals and oncologists with the latest
real-world data and strategies in the evolving treatment paradigm.
Participants will leave with ability to understand and utilize
recent real world and clinical trial data, implement best
strategies, tackle first line treatment decisions, as well as the
ability to help educate both their staff and colleagues, which will
ultimately increase organizational quality and, most importantly,
improve access and outcomes in patients with HR+/HER2- metastatic
Upon completion of this
activity, participants will be able to:
Examine the unmet clinical needs in
HR+/HER2- metastatic breast cancer and the impact of
inadequately treated disease on physical and mental health,
quality of life, costs and work productivity
Analyze recent efficacy and safety
data on CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer
Explore real-world evidence derived
from real-world data supplementing clinical trial evidence
related to the benefits and risks of CDK 4/6 inhibitors in
HR+/HER2- metastatic breast cancer
Evaluate best practices for
analyzing, interpreting and utilizing real-world data in
addition to data collected from clinical trials related to CDK
4/6 inhibitors in metastatic breast cancer in terms of study
design, validity, data sources, and implications for everyday
managed care and oncology practice
Compare and contrast adverse events
associated with CDK 4/6 inhibitors in HR+/HER2- metastatic
breast cancer in order to improve patient adherence and quality
||Adam Brufsky, MD, PhD
Professor of Medicine
Co-Director, Comprehensive Cancer Center
UPMC Hillman Cancer Center
Magee Women’s Hospital
University of Pittsburgh School of Medicine
has served as a consultant for Novartis, Pfizer, Lilly,
Roche, Sanofi, AstraZeneca, Daiichi Sankyo, and Seattle
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue